Chongqing Haisco Pharmaceutical Group Deal History & Licensing Activity
Chongqing Haisco Pharmaceutical Group is a biotech headquartered in China. Over the past three years, Chongqing Haisco Pharmaceutical Group has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Small Molecules
Focus Area
Other
Chongqing Haisco Pharmaceutical Group Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chongqing Haisco Pharmaceutical Group in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| dual PDE3/4 inhibitor | Haisco | Small Molecules | Phase 2 | license | Jun 12, 2026 |
| Multi-program collaboration (5 programs) | Eli Lilly | Small Molecules | Discovery | collaboration | May 15, 2026 |
Chongqing Haisco Pharmaceutical Group Pipeline Focus
Therapeutic areas and modalities where Chongqing Haisco Pharmaceutical Group is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Chongqing Haisco Pharmaceutical Group's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Chongqing Haisco Pharmaceutical Group Licensing & Deal Activity
Chongqing Haisco Pharmaceutical Group is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Chongqing Haisco Pharmaceutical Group ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chongqing Haisco Pharmaceutical Group include Other (3 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, Chongqing Haisco Pharmaceutical Group has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chongqing Haisco Pharmaceutical Group and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Chongqing Haisco Pharmaceutical Group's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.